Table 2 Baseline clinical characteristics of included studies
Study name | Age (y; m) | Female (n, %) | BMI (kg/m2; m) | DM (n, %) | Current smoker (n, %) | Prior MI (n, %) | Chronic kidney disease (n, %) | ACS (n, %) |
|---|---|---|---|---|---|---|---|---|
HOST-REDUCE-POLYTECH-ACS [7] | 58.8 | 252 (10.7) | 25.8 | 990 (42.3) | 838 (35.8) | 90 (3.8) | 64 (2.7) | 2338 (100) |
TWILIGHT [11] | 65.2 | 1698 (23.9) | 28.6 | 2620 (36.8) | 1548 (21.8) | 2040 (28.7) | 1145 (16.8) | 4614 (64.8) |
TICO [9] | 61 | 628 (20.5) | 24.9 | 835 (27.3) | NA | 113 (3.7) | 620 (20.3) | 3056 (100) |
TOPIC [13] | 60 | 114 (18) | 27.2 | 177 (27) | 286 (44) | NA | NA | 646 (100) |
TROPICAL-ACS [14] | 58.8 | 2052 (78.6) | 28.3 | 527 (20.2) | 1182 (45.3) | 293 (11.2) | 67 (2.6) | 2610 (100) |
SMART CHOICE [8] | 64.5 | 795 (26.6) | 24.6 | 1122 (37.5) | 791 (26.4) | 127 (4.2) | 97 (3.2) | 1741 (58.2) |
STOPDAPT-2 [10] | 68.6 | 672 (22.3) | 24.3 | 1159 (38.5) | 710 (23.6) | 406 (13.5) | 166 (5.5) | 1148 (38.2) |
GLOBAL-LEADERS [12] | 64.6 | 3714 (23.3) | 28.2 | 4038 (25.3) | 4169 (26.1) | 3710 (23.2) | 2171 (13.6) | 7484 (46.9) |